Evidence map›Paper›PMID 39905065›Full record

ArticleScientific reports2025

Cost-reduction strategy to culture patient derived bladder tumor organoids.

Mahsa Mollapour Sisakht, Fatemeh Gholizadeh, Shirin Hekmatirad, Tokameh Mahmoudi, Saeed Montazeri, Laleh Sharifi, Hamed Daemi, Shahla Romal, Mohammad Hosein Yazdi, Mohammad Ali Faramarzi and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Organoid scaffold materials: research and application.Frontiers in bioengineering and biotechnology · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mahsa Mollapour SisakhtBiotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. mmollapour@farabi.tums.ac.ir.
Fatemeh GholizadehStem Cell and Regenerative Medicine innovation center, Tehran University of Medical Sciences, Tehran, Iran.
Shirin HekmatiradStem Cell and Regenerative Medicine innovation center, Tehran University of Medical Sciences, Tehran, Iran.
Tokameh MahmoudiDepartment of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Saeed MontazeriUro-oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Laleh SharifiUro-oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Hamed DaemiDepartment of Cell Engineering, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Shahla RomalDepartment of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Mohammad Hosein YazdiBiotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Ali FaramarziBiotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Ahmad Reza ShahverdiBiotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Amir Ali HamidiehBiotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Funding

Erasmus+ NL ROTTERD01Tehran University of Medical Sciences and Health Services 67742
6 · The paper itself

Abstract

Organoids as self-organized structure derived from stem cells can recapitulate the function of an organ in miniature form which have developed great potential for clinical translation, drug screening and personalized medicine. Nevertheless, the majority of patient-derived organoids (PDOs) are currently being cultured in the basement membrane matrices (BMMs), which are constrained by xenogeneic origin, batch-to-batch variability, cost, and complexity. Besides, organoid culture relies on biochemical signals provided by various growth factors in the composition of medium. We propose sodium alginate hydrogel scaffold in addition to the fibroblast conditioned medium (FCM)-enriched culture medium that is inexpensive and easily amenable to clinical applications for the culture of bladder cancer PDOs. PDOs grown in sodium alginate and FCM based medium have proliferation potential, growth rate, and gene expression that are similar to PDOs cultured in BME. According to the results, sodium alginate has substantial mechanical properties and reduces variance in early passage bladder tumor organoid cultures collected from patients. Furthermore, using FCM based medium as an alternative solution to eliminate some essential growth factors can be considered, especially for low-resource situation and develop cost effective tumor organoids.

Indexed as

Cell Culture TechniquesOrganoidsUrinary Bladder NeoplasmsAlginatesCell ProliferationCulture Media, ConditionedHumansHydrogelsAlginatesCulture Media, ConditionedHydrogelsAlginateBladder tumorFibroblast conditioned mediumOrganoids

Identifiers

PMID39905065
PMCPMC11794879

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.